Olshan Represents Client in $75 Million Registered Rights Offering

Olshan represented Summit Therapeutics Inc. (NASDAQ: SMMT), a clinical-stage drug discovery and development company, in the commencement of its rights offering earlier this week. The rights offering to purchase shares of Summit’s common stock has a total offering value of up to $75 million. Corporate associate Zachary Freedman assisted in this matter.